modelA12AA01

Diagram of A12AA01

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:CalciumPhosphate
ATC code:A12AA01
route:oral
compartments:1
dosage:500mg
volume of distribution:0.2L
clearance:0.007L/min
other parameters in model implementation

Calcium phosphate is an inorganic mineral salt used as a calcium supplement in the treatment and prevention of calcium deficiency. It is utilized in various formulations (tribasic, dibasic, monobasic) for dietary supplementation, antacid, and as a pharmaceutical excipient. Not typically considered a drug with systemic pharmacological action, it is approved and widely used today as a supplement rather than a primary therapeutic agent.

Pharmacokinetics

No detailed pharmacokinetic model or parameter has been directly reported for calcium phosphate in humans, since its main function is to provide elemental calcium, which is absorbed via the gastrointestinal tract. The PK parameters below are estimated based on literature for oral calcium salts in healthy adults.

References

  1. Hicks, J, et al., & Flaitz, C (2004). Biological factors in dental caries: role of remineralization and fluoride in the dynamic process of demineralization and remineralization (part 3). The Journal of clinical pediatric dentistry 28(3) 203–214. DOI:10.17796/jcpd.28.3.w0610427l746j34n PUBMED:https://pubmed.ncbi.nlm.nih.gov/15163148

  2. Liu, Y, et al., & Hunziker, EB (2018). The kinetics and mechanism of bone morphogenetic protein 2 release from calcium phosphate-based implant-coatings. Journal of biomedical materials research. Part A 106(9) 2363–2371. DOI:10.1002/jbm.a.36398 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29569828

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)